{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:13:39Z","timestamp":1793816019269,"version":"4.6.1"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Cancer therapy\u2013related cardiac dysfunction (CTRCD) is a potentially serious cardiotoxicity of treatments for <jats:italic>ERBB2<\/jats:italic>-positive breast cancer (formerly <jats:italic>HER2<\/jats:italic>). Identifying early biomarkers of cardiotoxicity could facilitate an individualized approach to cardiac surveillance and early pharmacologic intervention. Circulating cell-free DNA (cfDNA) of cardiomyocyte origin is present during acute cardiac injury but has not been established as a biomarker of CTRCD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine whether circulating cardiomyocyte cfDNA is associated with CTRCD in patients with <jats:italic>ERBB2<\/jats:italic>-positive breast cancer treated with anthracyclines and <jats:italic>ERBB2<\/jats:italic>-targeted therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>A prospective cohort of 80 patients with <jats:italic>ERBB2<\/jats:italic>-positive breast cancer enrolled at an academic cancer center between July 2014 and April 2016 underwent echocardiography and blood collection at baseline, after receiving anthracyclines, and at 3 months and 6 months of <jats:italic>ERBB2<\/jats:italic>-targeted therapy. Participants were treated with doxorubicin-based chemotherapy followed by trastuzumab (+\/\u2212 pertuzumab). The current biomarker study includes participants with sufficient biospecimen available for analysis after anthracycline therapy. Circulating cardiomyocyte-specific cfDNA was quantified by a methylation-specific droplet digital polymerase chain reaction assay. Data for this biomarker study were collected and analyzed from June 2021 through April 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The outcome of interest was 1-year CTRCD, defined by symptomatic heart failure or an asymptomatic decline in left ventricular ejection fraction (\u226510% from baseline to less than lower limit of normal or \u226516%). Values for cardiomyocyte cfDNA and high-sensitivity cardiac troponin I (hs-cTnI) measured after patients completed treatment with anthracyclines were compared between patients who later developed CTRCD vs patients who did not using the Wilcoxon rank sum test, and the association of post-anthracycline cardiomyocyte cfDNA level with CTRCD was estimated using logistic regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 71 patients included in this study, median (IQR) age was 50 (44-58) years, all were treated with dose-dense doxorubicin, and 48 patients underwent breast radiotherapy. Ten of 71 patients (14%) in this analysis developed CTRCD. The level of cardiomyocyte cfDNA at the post-anthracycline time point was higher in patients who subsequently developed CTRCD (median, 30.5 copies\/mL; IQR, 24-46) than those who did not (median, 7 copies\/mL; IQR, 2-22; <jats:italic>P<\/jats:italic>\u2009=\u2009.004). Higher cardiomyocyte cfDNA level after completion of anthracycline chemotherapy was associated with risk of CTRCD (hazard ratio, 1.02 per 1-copy\/mL increase; 95% CI, 1.00-1.03; <jats:italic>P<\/jats:italic>\u2009=\u2009.046).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This study found that higher cardiomyocyte cfDNA level after completion of anthracycline chemotherapy was associated with risk of CTRCD. Cardiomyocyte cfDNA quantification shows promise as a predictive biomarker to refine risk stratification for CTRCD among patients with breast cancer receiving cardiotoxic cancer therapy, and its use warrants further validation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02177175\">NCT02177175<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2023.1229","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T15:32:59Z","timestamp":1685547179000},"page":"697","source":"Crossref","is-referenced-by-count":22,"title":["Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy\u2013Related Cardiac Dysfunction in Patients Undergoing Treatment for <i>ERBB2<\/i>-Positive Breast Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Anthony F.","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary R.","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaya S.","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau T.","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Ramanathan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Oeffinger","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke Cancer Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Steingart","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"hbr230006r1","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline.","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"hbr230006r2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.amjcard.2021.02.013","article-title":"Racial and socioeconomic disparities in cardiotoxicity among women with HER2-positive breast cancer.","volume":"147","author":"Al-Sadawi","year":"2021","journal-title":"Am J Cardiol"},{"issue":"26","key":"hbr230006r3","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1200\/JCO.2016.67.4846","article-title":"Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis.","volume":"34","author":"Guenancia","year":"2016","journal-title":"J Clin Oncol"},{"issue":"18","key":"hbr230006r4","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of cell-free DNA analysis to cancer treatment.","volume":"379","author":"Corcoran","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"hbr230006r5","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1038\/s41467-018-07466-6","article-title":"Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease.","volume":"9","author":"Moss","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"hbr230006r6","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/s41467-018-03961-y","article-title":"Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA.","volume":"9","author":"Zemmour","year":"2018","journal-title":"Nat Commun"},{"issue":"16","key":"hbr230006r7","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"hbr230006r8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1373\/clinchem.2017.276972","article-title":"Comprehensive age and sex 99th percentiles for a high-sensitivity cardiac troponin I assay.","volume":"64","author":"Estis","year":"2018","journal-title":"Clin Chem"},{"issue":"12","key":"hbr230006r9","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography\u2019s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"issue":"4","key":"hbr230006r10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.echo.2018.12.009","article-title":"Assessment of early radiation-induced changes in left ventricular function by myocardial strain imaging after breast radiation therapy.","volume":"32","author":"Yu","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"issue":"8","key":"hbr230006r11","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"hbr230006r12","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.cjca.2019.10.016","article-title":"Clinical significance of circulating cardiomyocyte-specific cell-free DNA in patients with heart failure: a proof-of-concept study.","volume":"36","author":"Yokokawa","year":"2020","journal-title":"Can J Cardiol"},{"issue":"8","key":"hbr230006r13","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","article-title":"Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy.","volume":"35","author":"Zardavas","year":"2017","journal-title":"J Clin Oncol"},{"key":"hbr230006r14","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3389\/fphys.2019.01049","article-title":"Cardiomyocyte-derived exosomes: biological functions and potential therapeutic implications.","volume":"10","author":"Yu","year":"2019","journal-title":"Front Physiol"},{"issue":"21","key":"hbr230006r15","doi-asserted-by":"publisher","first-page":"8062","DOI":"10.3390\/ijms21218062","article-title":"Putative origins of cell-free DNA in humans: a review of active and passive nucleic acid release mechanisms.","volume":"21","author":"Grabuschnig","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2805581\/jamacardiology_yu_2023_br_230006_1688580111.97429.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T15:04:24Z","timestamp":1689174264000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2805581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.1229","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}